Abivax S.A.
AAVXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $11 | $5 | $5 | $0 |
| % Growth | 133.5% | 0.8% | 12,286.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $11 | $4 | $5 | -$0 |
| % Margin | 100% | 97.2% | 98.5% | -321.6% |
| R&D Expenses | $147 | $103 | $49 | $47 |
| G&A Expenses | $33 | $22 | $7 | $6 |
| SG&A Expenses | $39 | $29 | $7 | $5 |
| Sales & Mktg Exp. | $6 | $6 | $0 | -$1 |
| Other Operating Expenses | -$2 | -$0 | $0 | $0 |
| Operating Expenses | $184 | $127 | $57 | $52 |
| Operating Income | -$173 | -$127 | -$57 | -$52 |
| % Margin | -1,602.9% | -2,756.5% | -1,236% | -141,045.9% |
| Other Income/Exp. Net | -$3 | -$25 | -$0 | $7 |
| Pre-Tax Income | -$176 | -$152 | -$74 | -$46 |
| Tax Expense | $0 | -$4 | -$4 | -$4 |
| Net Income | -$176 | -$148 | -$70 | -$41 |
| % Margin | -1,633.1% | -3,197.1% | -1,524% | -111,775.7% |
| EPS | -2.8 | -3.43 | -3.13 | -2.47 |
| % Growth | 18.4% | -9.6% | -26.7% | – |
| EPS Diluted | -2.8 | -3.43 | -3.13 | -2.47 |
| Weighted Avg Shares Out | 63 | 43 | 22 | 17 |
| Weighted Avg Shares Out Dil | 63 | 43 | 22 | 17 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $0 | $0 |
| Interest Expense | $4 | $14 | $4 | $4 |
| Depreciation & Amortization | $1 | $1 | $0 | $0 |
| EBITDA | -$172 | -$133 | -$53 | -$39 |
| % Margin | -1,592.7% | -2,882.6% | -1,163.3% | -104,697.3% |